Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas
| Autor: | Fred P. Rosenfelt, Melissa Cervania, Sepehr Rokhsar, Andy Pao, Bekir Cinar, Jean Lopategui, Raju Pillai, Serhan Alkan, Munevver Cinar |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Cancer Research
Vincristine Sulfonamides Lymphoma B-Cell Genes myc Hematology Biology BCL6 medicine.disease Bridged Bicyclo Compounds Heterocyclic Lymphoma medicine.anatomical_structure Oncology Proto-Oncogene Proteins c-bcl-2 Apoptosis Cell culture hemic and lymphatic diseases Immunology medicine Cancer research Effective treatment Humans Doxorubicin B cell medicine.drug |
| Zdroj: | Leukemia research. 39(7) |
| ISSN: | 1873-5835 |
| Popis: | Double hit lymphoma or triple hit lymphoma (DHL/THL) is a rare form of aggressive B-Cell Lymphoma. Overexpression of MYC, BCL2 or/and BCL6 due to genomic rearrangements are the key molecular features of DHL/THL. Patients with DHL/THL show very aggressive disease course and poor survival due to the lack of effective treatment modalities. Here, we established new THL cell model and assessed its in vitro growth characteristics along with the DHL cell line in response to potent MYC inhibitors, 10058-F4 and JQ-1, and a BCL2 inhibitor, ABT-199, with or without chemotherapeutic agent vincristine or doxorubicin. We found that 10058-F4, JQ-1 or ABT-199 exposure as a single agent inhibited the growth of DHL/THL cells in a dose-dependent manner. Combined exposure of 10058-F4 or JQ-1 and ABT-199 as well as vincristine or doxorubicin markedly suppressed the growth of DHL/THL cells compared with the single treatment. As assessed by multiple approaches, apoptosis induced by ABT-199, 10058-F4 or JQ-1 was underlying cause of the observed growth suppression. These findings suggest that co-inhibition of MYC and BCL2 signaling is a promising therapeutic strategy for patients with DHL/THL lymphomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect